Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

Abstract Chemotherapy associated osteoporosis is a severe problem in patients with malignant diseases as it increases the risk for fractures and deteriorates quality of life. There are very limited data in the literature for the effect of chemotherapy on bone metabolism of adult patients with Non-Hodgkin Lymphoma (NHL). We prospectively evaluated bone remodeling pre- and post-chemotherapy in 61 patients with newly diagnosed NHL. First-line chemotherapy resulted in high bone turnover, which led to increased bone loss and reduced bone mineral density (BMD) of lumbar spine (L1-L4) and femur neck (FN). The reduction of L1-L4 and FN BMD post-chemo was more profound in males and in older patients (>55 years). Patients who received 8 cycles of chemotherapy had a greater reduction of L1-L4 and FN BMD as compared to 6 cycles. The administration of chemotherapy also resulted in a dramatic increase of bone resorption markers (CTX and TRACP-5b), bone formation markers, (bALP and Osteocalcin) and of osteoblast regulator Dickkopf-1. During study period, one patient had a pathological fracture in his right FN.

[1]  A. Zimran,et al.  Bone loss and hematological malignancies in adults: a pilot study , 2018, Supportive Care in Cancer.

[2]  M. Bøgsted,et al.  R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients , 2017, Leukemia & lymphoma.

[3]  S. Fosså,et al.  Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation , 2017, Acta oncologica.

[4]  C. Roux,et al.  Glucocorticoid-induced osteoporosis , 2015, RMD Open.

[5]  J. Westin,et al.  Bone mineral density screening should be routine in lymphoma patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  P. Fardellone,et al.  Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study. , 2014, Annals of Oncology.

[7]  J. Shah,et al.  Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. , 2013, Clinical lymphoma, myeloma & leukemia.

[8]  J. Fryzek,et al.  Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark , 2013, Clinical epidemiology.

[9]  M. Dimopoulos,et al.  Low bone mineral density and high bone turnover in patients with non-Hodgkin's lymphoma (NHL) who receive frontline therapy: Results of a multicenter prospective study , 2011 .

[10]  Naoto Endo,et al.  Relationship between radiological knee osteoarthritis and biochemical markers of cartilage and bone degradation (urine CTX-II and NTX-I): the Matsudai Knee Osteoarthritis Survey , 2009, Journal of Bone and Mineral Metabolism.

[11]  K. Stępień,et al.  Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis , 2009, Rheumatology International.

[12]  S. Fosså,et al.  Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy , 2009, British Journal of Cancer.

[13]  J. Shaughnessy,et al.  The role of Dickkopf-1 in bone development, homeostasis, and disease. , 2009, Blood.

[14]  M. Inaba,et al.  Serum Levels of TRAP5b, a New Bone Resorption Marker Unaffected by Renal Dysfunction, as a Useful Marker of Cortical Bone Loss in Hemodialysis Patients , 2008, Calcified Tissue International.

[15]  H. Brenner,et al.  Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. , 2008, Archives of internal medicine.

[16]  L. Melton,et al.  A reference standard for the description of osteoporosis. , 2008, Bone.

[17]  W. Murphy,et al.  Osteopenia and osteoporosis in untreated non-Hodgkin's lymphoma patients: An important and potentially treatable survivorship issue in lymphoma , 2007 .

[18]  Xianglin L. Du,et al.  Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures , 2007, Leukemia & lymphoma.

[19]  M. Dimopoulos,et al.  The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio , 2005, Leukemia.

[20]  C. Cooper,et al.  Use of Oral Corticosteroids and Risk of Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  J. Hahn,et al.  Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy. , 2004, The American journal of medicine.

[22]  J. Halleen Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. , 2003, Anticancer research.

[23]  R. Parker,et al.  Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. , 2001, The Journal of clinical endocrinology and metabolism.

[24]  C. Cooper,et al.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.

[25]  J. Pfeilschifter,et al.  Osteoporosis due to cancer treatment: pathogenesis and management. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Knip,et al.  Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. , 1999, The Journal of clinical endocrinology and metabolism.

[27]  C. Cooper,et al.  A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update , 1998, Journal of internal medicine.

[28]  E. Canalis Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. , 1996, The Journal of clinical endocrinology and metabolism.

[29]  J. Berenson Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients--the American experience. , 1996, British journal of clinical practice. Supplement.

[30]  M. Cobleigh,et al.  Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Gowen,et al.  Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. , 1989, The Journal of clinical investigation.

[32]  Bijvoet Ol,et al.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. , 1986 .

[33]  C. Blomqvist,et al.  LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASES , 1983, The Lancet.

[34]  Chad A. LaGrange,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[35]  A. Osborne Zoledronic acid , 2012, Reactions Weekly.

[36]  設樂 香織 Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients , 2011 .

[37]  P. Boonekamp,et al.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. , 1986, Bone and mineral.